NCT00111696 2012-03-14
Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma
MedImmune LLC
Phase 1 Completed
Clinical Trials
5 trialsNCT00263783 2009-01-29
Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors
MedImmune LLC
Phase 1 Completed
NCT00284817 2008-05-29
Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer
MedImmune LLC
Phase 1/2 Completed
NCT00066196 2008-01-15
Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
MedImmune LLC
Phase 2 Completed
NCT00072930 2008-01-15
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
MedImmune LLC
Phase 2 Completed